FORMULATION ARTICLES
-
![Genetic engineering-GettyImages-1133966737]( "The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs")
The Great Cell Therapy Reset: Solving The Industrial Math Of Living DrugsThe cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).
-
![Genetic engineering, dna-GettyImages-1310083278]( "Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes Next")
Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes NextOligonucleotide therapies have proven clinical value, but scaling beyond rare disease remains hard. William Soliman, Ph.D., BCMAS, breaks down the manufacturing, delivery, and CMC realities shaping what comes next.
-
![RNA strands, SiRNA, mRNA, CRISPR delivery-GettyImages-2151198841]( "In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors")
In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid TumorsBy injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.
-
![cancer cell screening, disease treatment medical-GettyImages-2189938556]( "Powering Cell Therapies With RNA: A New Code For Engineered Immunity")
Powering Cell Therapies With RNA: A New Code For Engineered ImmunityRNA is redefining cell therapy engineering—enabling transient, programmable control of immune and stem cells while simplifying manufacturing, improving safety, and accelerating scalable, virus-free workflows.
-
![digital exchange, money transfer-GettyImages-2148127398]( "Why RNA Tech Transfer Is So Hard — And How the Field Can Fix It")
Why RNA Tech Transfer Is So Hard — And How the Field Can Fix ItA closer look at why RNA tech transfer remains one of the field’s toughest bottlenecks — and the practical steps developers and CDMOs can take to finally streamline the path to GMP.
-
![GettyImages-1128195910-vial-white-powder-lyophilization]( "Four Reasons You Should Choose Lyophilization for Your Next Project")
Four Reasons You Should Choose Lyophilization for Your Next ProjectLyophilization ensures product stability, extends shelf life, supports sensitive formulations, and simplifies storage and transport, making it a critical choice for modern drug development projects.
FORMULATION VIDEOS
In this clip, Sanofi’s Greg Troiano kickstarts our discussion on some of the advances he’s seen in the supply chain for linear mRNA-LNP products, both in terms of supply availability and supplier capability.
Dr. Jason Coleman, Clinical Application Scientist Lead with Precision NanoSystems, presents on an overview of the development and scale-up activities needed to progress this saRNA vaccine to the clinic.
There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.
How can PCR-based technology accelerate mRNA development and manufacturing and design principles/critical parameters to enable the rapid development of lipids for RNA formulation?
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1357908552]( "Leveraging Single-Use Technology For mRNA-LNP Drug Manufacturing")
Single-use technology is vital for ensuring the quality and expedited market entry of genomic medicines. Learn how LNP technology is paving the way for a new era of personalized, precise medicine.
-
![Science techonlogy-research-development-discovery-GettyImages-1209662272]( "Turbulent Mixing: Scaling Up Nanoparticle Manufacturing For The Future")
Choosing between turbulent and microfluidic mixing methods in your lipid nanoparticle (LNP) production can have a significant impact when scaling up production.
-
![Cleanroom Scientists At Computer GettyImages-1294339594]( "Drug Discovery And Screening, A Digital Era For RNA-LNP Therapeutics")
Learn about the key stages of drug discovery and screening as well as how to overcome bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.
-
![mRNA GettyImages-1428646288]( "Establishing Analytical Methods For mRNA-Based Therapies")
Here, we provide a detailed description of assays for sequence identification and LNP composition in mRNA-LNP products that support the development of safe and effective mRNA therapies.
-
![GettyImages-1317697233-cancer-t-cells]( "A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy")
We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.
-
![GettyImages-1409578453-mRNA-LNP-lipid-nanoparticle-RNA therapy]( "Formulation Process And Analytical Development Capabilities")
Explore process and analytical development capabilities that can help you advance your formulation to GMP Manufacturing.
-
![GettyImages-1127105013-lab-computer-research-scientist]( "Co-Precipitation Of Metal Carbonate Templated Protein Microparticles")
Explore the automated production of protein microparticles using an innovative method that offers a standardized and scalable solution for co-precipitation in biopolymer particle fabrication.
